Abstract 1364P
Background
SAF-189s is a next-generation inhibitor of ALK/ROS1 tyrosine kinase, which has been shown to have anti-tumor activity against ALK/ROS1 fusion-positive non-small-cell lung cancer (NSCLC), including CNS activity due to its ability to penetrate the blood-brain barrier. Here we present a circulating tumor DNA (ctDNA) biomarker analysis of patients (pts) with advanced, ALK-rearranged NSCLC treated in phase 2a study.
Methods
Tumor tissue samples were collected from all enrolled pts for ALK-fusion detection by VENTANA ALK (D5F3) IHC assay. Plasma samples were collected at baseline and disease progression. Next-generation sequencing for ctDNA was done using Lung cancer 180-gene panel (Genetron). PFS was evaluated according to ALK alteration status.
Results
By the cut-off date of Dec 13th, 2021 (median PFS follow-up 11 mo), a total of 143 NSCLC ALK-fusion positive pts had been enrolled and treated with SAF-189s (80 mg, n=19; 120 mg, n=47, 160 mg, n=64; 210 mg, n=13), including 100 ALKi-naïve pts and 43 ALKi-refractory pts (received crizonitib and/or next-generation ALKi). ctDNA at baseline was tested in 143 pts with a ALK-fusion positivity rate of 53.8% (77/143). The main fusion partner of ALK was EML4, accounting for 93.6% (73/78). The most common fusion variants were v3 (34.5%, 27/78), v1 (28.2%, 22/78), and v2 (10.3%, 8/78). Pts with v1 variants showed a longer mPFS than v3 variants (16.5 mo vs. 13.8 mo, p=0.188). There was no significant difference in the distribution of ALK fusion variants between ALKi-naïve and ALKi-refractory groups. Of 25 pts who progressed with SAF-189s, two ALK mutations, G1202R and I1179T, were newly identified in 3 pts. I1179T has not been previously reported and is speculated to be a novel ALK-resistant mutation. TP53 co-mutations were detected in 47% pts, but it was not shown to have a significant effect on outcomes. Gene co-occurrence survival analysis showed that mPFS of pts harboring FAT3/FAT4 mutations were significantly shorter than those without FAT3/FAT4 mutations (8.9 mo vs 16.5 mo, p=0.012).
Conclusions
Clinical utility of ctDNA was demonstrated, not only at baseline by identifying fusion types and subgroups of ALK+ NSCLC pts that may benefit more from SAF-189s, but also at progression by tracking ALK-resistant mutations.
Clinical trial identification
NCT04237805.
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
Funding
Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1078TiP - Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 19
1079TiP - A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
Presenter: Shiraj Sen
Session: Poster session 19
1080TiP - An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
Presenter: Vladimir Galvao
Session: Poster session 19
1325P - Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
Presenter: James Chih-Hsin Yang
Session: Poster session 19
1326P - Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
Presenter: David Planchard
Session: Poster session 19
1327P - First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)
Presenter: Daniel Breadner
Session: Poster session 19
1328P - Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib
Presenter: Meredith LaRose
Session: Poster session 19
1329P - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
Presenter: Lucia Nogova
Session: Poster session 19
1330P - Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)
Presenter: Caicun Zhou
Session: Poster session 19